SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
December 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results
August 06, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
July 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak
June 18, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Present at the JMP Securities Life Sciences Conference
June 16, 2015 11:40 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...